Hepatitis B as an acute and chronic communicable disease, has been a worldwide health problem estimated to lead to between 500,000 to 1.2 million deaths every year through causing chronic hepatitis, cirrhosis and hepatocellular carcinoma[@b1]. The prevalence of HBV infection varies significantly in different areas: prevalence of chronic infection with HBV estimates range between 0.1--0.7% in Western, Northern, and Central Europe, while those considerably higher in Eastern and Southern European countries, such as Italy (0.2--4.3%), Turkey (2.5--9%), and Romania (5.6%)[@b2][@b3]. In Alaska, 41% had anti-HBs levels of \>10 mIU/ml 7 to 9 years after booster vaccination at birth[@b4], even 51% had this protective levels 30 years after receiving the primary series without subsequent doses in Alaska native persons[@b5]. In China, the HBsAg carrier rate was 8.75% in 1979, 9.75% in 1992, and 7.18% in 2006[@b6]; in Taiwan, the values are as high as 15--20% in adults[@b7]; and in the Middle East and North Africa region, the HBV infection estimates are various such as 9.8% in Egypt, 7.4% in Iran, 2.4% in Lebanon and 6.9% Libya from the prisoners; 50.7% in Iran, 8.6% in Israel, 2.8% in Lebanon, 4.5% in Libya, 2.6% in Palestine, 6.1% in Saudi Arabia from the injecting drug users[@b8]. In Gambia, 13.2% were found to carry HbsAg[@b9] and national infant HBV vaccination controlling chronic infection had 94% vaccine efficacy[@b10]. HBV can be transmitted in many ways, with sexual intercourse and mother-to-child transmission being the most common. Between 15% and 40% of those infected develop acute or chronic liver disease and liver failure, cirrhosis or hepatocellular carcinoma may result.

Many countries have gradually adopted the HBV vaccine in national immunization programs since the World Health Organization (WHO) recommended vaccination for children in 1990s. Most individuals with chronic hepatitis B are asymptomatic and therefore ignorant of their infection status but HBV vaccination, if used for primary prevention, can significantly lower the risk of infection. HBV vaccination triggers antibody response and antibody to hepatitis B surface antigen (anti-HBs) levels ≥10 IU/L are usually regarded as seroprotection for most vaccinees.

Vaccination efficacy among children has been widely studied, but there remains a large proportion of adult populations who are as yet unvaccinated. A previous meta-analysis in 2002 observed many factors influencing response to hepatitis B vaccine, especially a decrease response to recombinant HBV vaccine at higher ages[@b11], which suggested that earlier vaccination should be prioritized for prevention at the population level. However, in the last decade, numerous emerging reports, which focused on the seroprotection rate of hepatitis B vaccine in adults[@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48], are still inconclusive to immunize what adults are the most appropriate in order to increase the seroprotection rate. Factors influencing immunologic response to hepatitis B vaccine in adults have been inconsistently examined in existing studies. In this study, we conducted a systematic review and meta-analysis to update and assess a more precise estimation of factors that influence the response to HBV vaccine.

Material and Methods
====================

Search strategy
---------------

To find all relevant publications that investigated the association between adult and hepatitis B vaccine and seroprotection, a systematic literature search was independently conducted by two individual investigators with the same method in PubMed, Embase and Cochrane Library using the keywords "hepatitis B vaccine", "HBV", "adult", "anti-HBs" were used. Data were collected from the full-published paper and no language or race restriction was used. Bibliographies of relevant review articles were also screened to supplement the electronic searches.

Inclusion criteria
------------------

Included studies met the following criteria (1) original research papers; (2) prospective or retrospective studies, including cohorts and trials; (3) sample size ≥10; (4) healthy subjects, pregnant women, participants with diabetes, chronic renal failure or other diseases but without congestive hepatopathy or infectious diseases; (5) mean sample population age ≥18 years; (6) populations are largely vaccine naive; (7) seroprotection (generally defined as antibody-HBs at a titer of \>10 mlU/mL) is assessed at least one month after last recombinant vaccine dose in the majority of participants.

Article screening
-----------------

Citations were electronically downloaded into reference management software and duplicate citations were electronically/manually excluded. Where studies had multiple reports, the most recent or most complete article was retained. The remaining citations were screened independently by two reviewers using pre-defined criteria. Full-text versions of potentially relevant citations were obtained and again screened independently by two reviewers according to pre-defined criteria. Disagreement was resolved by the opinion of a third reviewer.

Data extraction and quality assessment
--------------------------------------

The data was independently extracted and then cross-checked by two investigators according to a standard format as follows: author, publication year, age, country, male/female participants, body mass index (BMI), vaccination schedule, time of immunological assessment after last vaccine dose, vaccine characteristics and injection pathwayIf necessary data were unavailable in articles, a request was sent to the author for relevant data. The definition of age strata varied among studies. We considered age ≥16 years as adult and age ≥40 years as a default definition of older age for study participants. We considered individuals with anti-HBs titers ≥10 IU/L to be seroprotective after completion of vaccination against HBV. In a few articles, those data are also available if the seroconversion was defined as anti-HBs titers ≥10 IU/L. The articles were divided into four quality levels such as high, moderate, low, and very low by GRADE evidence profile, which allocates original ranks of low score to observational studies and high score to RCTs[@b49].

Statistical analysis
--------------------

In this meta-analysis, we calculated the relative risks (RRs) and 95% confidence intervals (CIs) by comparing the valid and invalid participators in the experimental group and control group of recruited articles. Statistical heterogeneity in the studies was examined by the Q statistic. We evaluated the heterogeneity in these studies by this method, *I*^*2*^ = 100 %\*(Q-df)/Q. A fixed-effect model was used to analyze the data if there was no statistical difference of heterogeneity (p ≥ 0.05). Otherwise, a random-effect model would be selected.

Subgroups analyses were defined in advance/defined according to the reported data, and studies or results were grouped according to age (older or younger than 40), sex, smoking status, alcoholism, vaccine administration (0-1-12/0-1-6 vaccination schedule), geographical location (Asians/Non-Asian). Sensitivity analysis was performed to estimate the stability of the model by removing each study in turn. Additionally, publication bias was assessed through the funnel plot and Egger's linear regression test[@b50]. All statistical analyses were conducted by Stata 12.0 software.

Results
=======

Characteristics of eligible studies
-----------------------------------

We finally identified 21053 adults from 37 articles up to June 30, 2015 through electronic and manual searches ([Fig. 1](#f1){ref-type="fig"}). Nine hundred and forty-six studies were excluded according to the mentioned criteria. The characteristics of included studies for this meta-analysis are presented in [Table 1](#t1){ref-type="table"} and the majority of the studies were assessed as being of good quality ([Table 2](#t2){ref-type="table"}).

The studies were largely prospective cohort (n = 5), retrospective cohorts (n = 23), or randomized trials (n = 10). Studies varied considerably in size and were conducted among many countries. The three vaccine doses tended to be administered either at months 0, 1, 6 or 0, 1, 12 and recombinant vaccine doses ranged from 10 μg to 40 μg.

Meta-analysis results
---------------------

### Heterogeneity test result and subgroup analysis

The *Q*-tests of heterogeneity were marked in partial groups and then the pooled RRs were calculated by the random-effect models and fixed-effect models. Meta-analysis revealed that vaccine non-response rates were significantly greater in older participants (age ≥40 vs. \<40 years, RR:1.86, 95% CI:1.55 to 2.23, *I*^*2*^ = 56%, *P*  = 0.001; age ≥30 vs. \<30 years, RR:1.77, 95% CI:1.48 to 2.10, *I*^*2*^ = 37%, *P*  = 0.074; age ≥60 vs. age\<60 years RR:1.30, 95% CI:1.01 to 1.68 *I*^*2*^ = 33.4%, *P*  = 0.199). Non-response was also more likely among males (male adults vs. female adults, RR:1.40, 95% CI:1.22 to 1.61, *I*^*2*^ = 44.3%, *P*  = 0.005); overweight participants (BMI ≥ 25 adults vs. \<25, RR:1.56, 95% CI:1.12 to 2.17, *I*^*2*^ = 77.3%, *P* \< 0.001); smokers (smoker vs. nonsmoker, RR:1. 53, 95% CI:1.21 to 1.93, *I*^*2*^ = 52.1%, *P*  = 0.01) and those with concomitant disease compared to healthy participants (RR:1.39, 95% CI:1.04 to 1.86, *I*^*2*^ = 63.4%, *P*  = 0.002) ([Figs 2a](#f2){ref-type="fig"}, [3a](#f3){ref-type="fig"}, [4a,b,d](#f4){ref-type="fig"} and [5a,d](#f5){ref-type="fig"}). However, there were no differences in response to HBV by alcoholic status (alcoholic vs. nonalcoholic, RR:0.90, 95% CI:0.64 to 1.26, *I*^*2*^ = 0, *P*  = 0.941) or vaccination schedule (vaccine delivered at months 0-1-12 vs. 0-1-6, RR:1.39, 95% CI:0.41 to 4.67, *I*^*2*^ = 77.4%, *P*  = 0.004).

Subgroup analysis by study location and age indicates that older adults (≥40 years) from non-Asian countries revealed that in contrast with Asians, specially non-Asians in older adults (age ≥ 40) may be slightly less response to hepatitis B vaccine than younger adults (age \< 40) (RR:2.02, 95% CI:1.59--2.58; RR:1.60, 95% CI:1.24--2.08), consistent with the region result of older adults (age ≥ 30) (RR:2.16, 95% CI:1.66--2.80; RR:1.46, 95% CI:1.15--1.86). Particularly comparing with Asians, the male in non-Asians has a similar nonresponse to females (RR:1.42, 95% CI:1.18--1.71; RR:1.40, 95% CI:1.11--1.77).

When studies were subdivided by study design results were consistent and lower response was seen among studies with older participants and male participants and again, no difference was observed by alcoholic status ([Figs 2b](#f2){ref-type="fig"}, [3b](#f3){ref-type="fig"}, [4c,d](#f4){ref-type="fig"} and [5a,b](#f5){ref-type="fig"}).

### Sensitivity analysis and publication bias

Sensitivity analysis was conducted to estimate the stability of the results and indicated no significant change if any one study was excluded. Funnel plot asymmetry was assessed by means of Egger's linear regression test and showed that there was significant publication bias in the following groups: age of 40 years, gender and BMI (age40: *t*  = 2.54, *P*  = 0.019; sex: *t*  = 2.99, *P*  = 0.006; BMI: *t*  = 2.70, *P*  = 0.025).

Discussion
==========

When stratified by demographic features, our study showed a lower response in older adults (especially age ≥ 40), male adults and overweight adults (BMI ≥ 25), smoker and adults with concomitant disease after completion of vaccination against hepatitis B.

Our study indicated that young adults have a higher seroprotection rate to hepatitis B vaccine than other age groups (age30: RR = 1.77; age40: RR = 1.86; age60: RR = 1.30). It means that the earlier adult vaccination was inoculated at an age, the better efficiency is. The lower responsiveness to hepatitis B vaccines in older adults might result from the waning immunity with age. In previous studies, it did not find a significant association between age and the immune response[@b43][@b44]. The reason may be that most adults in the study were under the age of 40 years. However, in an observational prospective study of 666 participants, the percentage of nonresponders elevated gradually with age[@b51]. Another study aligned with our findings also found that younger age and female gender were predictive of better response[@b52]. It indicated in our study that population in non-Asians were both better in age of 40 or 30 years (age30: RR = 2.16; age40: RR = 2.06). Surprisingly our result also showed that the response rate in the younger adults (age \< 60) was better than those older (age ≥ 60), different from the previous study[@b44]. Some studies reported seroprotection rates of hepatitis B vaccine in older adults (aged ≥ 60 years) range from 30% to 80% and rely on these factors such as study population, vaccination plan, vaccination history and type of vaccine[@b40].

Besides age in our study, male gender both in Asians and non-Asians may be associated with nonresponse to hepatitis B vaccine. It may be owing to the opposite effects of sex hormone androgen and estrogen. This difference is experimentally repeated in animal models, which indicated to be activated by sex hormones in genetic regulation. Moreover, there are numerous immunological genes appearing on the X chromosome while few ones are mapped on the Y chromosome. Estrogen activates monocytes to secrete IL-10, which induces IgG and IgM secretion through B-cells in turn[@b53], while testosterone damages the production of IgG and IgM from B-lymphocytes, as well as restrains producing IL-6 from monocytes[@b54]. The hormones' joint effects on the epigenetic adjustment of genetic expression, and gene structure on the X chromosome differing between XX females and XY males, will partly account for vaccine response heterogeneity in gender[@b55]. Based on our results, future programme should be emphasized on males both Asians and non-Asians, who tend to have less response to hepatitis B vaccine.

BMI might influence the level of vaccine response[@b25]. The low response to vaccination of overweight on vaccine could be due to the main distribution of the vaccine in fat not in muscle. This could hinder absorption and enable denaturation of the vaccine antigen by enzymatic action[@b25]. Another possible interpretation is damaged proliferation and function of the antibody-secreting plasma cells.

The lower immunogenicity of hepatitis B vaccine was linked with smoking and male gender. In smokers, smoking can affect cells and humoral mediated immune responses in humans and animals. Nicotine restrains the antibody-forming cell response by damaging antigen-mediated pathway in T cells and intracellular calcium response. In addition, a high prevalence of HBV markers has been reported in alcoholics. Persistent alcohol intake could restrain immune responses especially in female[@b56]. But some studies also reported that difference was undetected between alcohol consumption and seroprotection of hepatitis B vaccination[@b31][@b38]. In this study, the inapparent association within alcoholic subgroup may result from the small sample size and drinking is not common in females.

Aside from those factors, patients with concomitant disease usually have a complicated and inconstant status due to diverse pathogenesis. Although some researches found no association between comorbidity and seroprotection[@b36][@b37], comorbidity may be a significant element decreasing the efficacy of hepatitis B vaccine from this analysis and others[@b23][@b27], which could bring immunity disturbance. However, the detailed mechanisms between the poor response to hepatitis B vaccine and adults suffering from concomitant disease are still incompletely understood.

What's more, the four reports regarding different vaccination schedules in adults such as 0-1-6 and 0-1-12 schedules are still controversial[@b13][@b39][@b47][@b48]. Three studies among them[@b13][@b39][@b47] observed no difference in seroconversion rates between these two schedules (as in these cases they were all nearly 100%), while another study[@b48] showed a higher seroconversion rate in individuals with the 0-1-12 schedule. Our meta analysis found no difference for seroconversion rate one month after the third injection both in 0-1-6 and 0-1-12 vaccination schedules. Thus in consideration of timing and vaccination compliance, the conventional 0-1-6 vaccination schedule could be still worth to be recommended.

Recently, emerging studies tended to suggest the genetic determinants of heterogeneity in response to the vaccines against hepatitis B. In twins study, 60% of the phenotypic variance was interpreted for the anti-HBs immune response by additive genetic while 40% by non-shared environmental effects[@b57]. Asians and non-Asians as study location may also play an important role in seroprotection efficiency of hepatitis B vaccine in adults. The percentage of nonresponders after hepatitis B vaccine remarkably varied in ethnic groups, which may result from the difference of environmental surroundings, the mutation rate and genetic variability, especially at the human leucocyte antigen (HLA) genetic region. However, it is also hard to accurately locate the variation affecting the HBV response in the HLA locus as a result of the long-range linkage disequilibrium in this area[@b58]. It needs further studies to explore.

In a word, the factors mentioned above suggested these factors consisting of elder adults, male, BMI ≥ 25, smoking and concomitant disease would be the significant variables reducing the immune response to hepatitis B vaccination. Those who are more likely to have non-response should be checked for seroprotection level and offered additional booster vaccinations. Thereby finding those without immunization and improving overall immunization rates across the population should be emphasized.

Our results should be interpreted in view of the following limitations. First, publication bias was identified among studies reporting rates by age groups, gender and BMI groups. Second, for the various subgroup analyses, sample size is diminished and therefore CIs are wide leading to less accurate estimates of response. Third, due to differences in lifestyle characteristics in different studies' population, significant heterogeneity was present in study, even among subgroup estimates. In addition, there were poor reporting in some included studies and limited inclusion in subgroup analyses such as BMI, smoking status, alcohol status and concomitant disease. What's more, several different vaccines were used in the different studies, which had different immunogenicity. Engerix B (with 20  μg HBsAg per dose) is more immunogenic than Recombivax (with 10 μg per dose), the difference being seen especially in older individuals. Twinrix is similar immunogenicity to Engerix-B. A multi-center study found that a S-PreS1/PreS2-vaccine (Hepacare) is also more immunogenic than Engerix B[@b2]. Despite limitations, in this work, we systematically sought out all published literature relevant to our research question and then carefully screened studies and extracted data in duplicate using protocols to ensure high quality and consistency in the extracted data. Missing data were sought from authors and studies results were statistically combined to provide robust estimates of the factors associated with poorer immunological response. To our knowledge, this is the first study to examine multiple factors associated with vaccine response and important differences have been found.

Conclusions
===========

Taken together, this meta-analysis indicated that there were lower seroprotection rates to hepatitis B vaccine in the subgroups of increasing aged adults, male, BMI ≥ 25, smoking and concomitant disease, and more vaccine doses, supplemental/additional strengthening immunity should be focused on this specific population. No difference in seroconversion rates between 0-1-6 and 0-1-12 vaccination schedule was observed, but in consideration of timing and vaccination compliance, the vaccination 0-1-6 schedule could be still worth to be recommended. In order to obtain accurate effectiveness of hepatitis B vaccine in adults, more large-scale studies should be conducted in the future.
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![(**a**) The relative risks of response to HBV vaccine between adults age ≥60 and adults age \<60. (**b**) The relative risks of response to HBV vaccine between male adults and female adults. (**c**) The relative risks of response to HBV vaccine between male adults and female adults grouped by study design. Comparing with female adults, The RRs suggest declined response to HBV vaccine among male adults both in cohort and RCT studies. (**d**) The relative risks of response to HBV vaccine between BMI ≥25 adults and BMI \<25 adults.](srep27251-f4){#f4}

![(**a**) The relative risks of response to HBV vaccine between smoker and nonsmoker. (**b**) The relative risks of response to HBV vaccine between alcoholic and nonalcoholic. (**c**) The relative risk of response to HBV vaccine between adults with concomitant disease and healthy adults. (**d**) The relative risk of response to HBV vaccine between 0-1-12 and 0-1-6 vaccination schedule.](srep27251-f5){#f5}

###### Summary of studies investigating the response to hepatitis B vaccine in adults.

  Author                                             Year  Studydesign                                                                                         Age (years)                                                    Populationcharacteristics                Country                             Male/Female                                              BMI                                     Schedule (months)           Follow-up (After last does of vaccine)  Vaccinedetail                                                                                     Injection pathway                                                                                                                                                Geometric mean titer (IU/L)                                                                                                                                                                                                                                                                                Seroprotection reached n/% (\>=10 mlU/mL)
  ------------------------------------------------- ------ ------------------------------------------------ ----------------------------------------------------------------------------------------------------------------- ---------------------------------------- ---------------- ------------------------------------------------- -------------------------------------------------------- ----------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------ ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Zajac B. A. *et al.*                               1986  Retrospective cohort                                                                                  20--70                                                       Healthy adults                           USA                                     NA                                                    NA                                           0-1-6                              1--6 months                10 μg recombinant vaccine                                                                                IM                                                                                                                            a\) 300 IU/L (2.5 ug);b) 350 IU/L (5 ug);c) 1250 IU/L (10 ug);d) 1000 IU/L (20 ug)                                                                                                                                                                                                                                            a\) 98% (2.5 ug);b) 89% (5 ug);c) 97% (10 ug);d) 87% (20 ug)
  Jilg W. *et al.*                                   1989  Randomized trials                                                                   a\) 24.7 ± 2.1 b) 24.4 ± 1.7 c) 24.6 ± 1.8                                     Healthy medical students                 Germany                     a\) 12/17;b) 16/14;c) 16/14                                       NA                             a\) 0-1-2-12; b) 0-1-6; c) 0-1-12                 12 months                 10 μg recombinant vaccine                                                                                IM                                                                                                                                      a\) 53 IU/I (0-1-2);b) 5846 IU/L (0-1-6);c) 19912 IU/L (0-1-12)                                                                                                                                                                                                                                                Seroconversion rate in all three groups was 100% after the third dose.
  Morris C. A. *et al.*                              1989  Retrospective cohort                                                                                  19--60+                                                      Health care volunteers                   United Kingdom                        79/136                                                  NA                                           0-1-6                              1--2 months                2 μg recombinant vaccine, Engerix-B                                                                      ID                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               80.9%
  Westmoreland D. *et al.*                           1990  Retrospective cohort                                                                                  17--71                                                       Occupational risk of infection           United Kingdom                       304/1016                                                 NA                                           0-1-6                               6--8 weeks                20 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               90.50%
  Guan R. *et al.*                                   1990  Retrospective cohort                                                                          40 ± 7.7 range: 23--54                                               Chronic renal failure                    Singapore                              11/18                                                  NA                                          0-1-2-6                               6 months                 40 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                 112 IU/L                                                                                                                                                                                                                                                                                                    69% (\>2.1 IU/L, 79%)
  Dahl-Hansen E. *et al.*                            1990  Randomized trials                                                                                     21--62                                                       Healthy adults                           Norway                                30/109                                                  NA                                           0-1-6                                3 months                 recombinant vaccine,20 μg Engerix-B and 10 μg Recombivax                                                 IM                                                                                                                                              a\) 189 IU/L (SKR 20 ug);b) 99 IU/L (MSD 10 ug)                                                                                                                                                                                                                                                                                        100.0%
  Dentico P. *et al.*                                1992  Randomized trials                                                                                     18--60                                                       Volunteer employees                      Italy                           a\) 43/57;b) 35/65                                            NA                                           0-1-6                              1--42 months               a\) 10 μg recombinant vaccineb) 20 μg recombinant vaccine                                                IM                                                                                                                                                a\) 1252 IU/L (10 ug);b) 1340 IU/L (20 ug)                                                                                                                                                                                                                                                                               a\) 87% (10 ug);b) 97% (20 ug)
  Roome A. J. *et al.*                               1993  Retrospective cohort                                                                         Mean: 39.3 range: 14--74                                              Healthy adults                           USA                                   510/18                                                  NA                                           0-1-6                              1--6 months                recombinant vaccine, Recombivax HB                                                                       NA                                                                                                                                                                 235 IU/L                                                                                                                                                                                                                                                                                                            88.1%
  McMaster K. R. 3rd *et al.*                        1993  Retrospective cohort                                                                                    NA                                                         Most firefighters                        USA                                     NA                                                    NA                                          0-1-2-6                             1--2 months                2 μg recombinant vaccine, Engerix-B                                                                      ID                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               90.5%
  Jaiswal S. B. *et al.*                             1995  Retrospective cohort                                                                                    NA                                                         Chronic renal failure                    India                                  29/11                                                  NA                                           0-1-6                                1 month                  40 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               50.0%
  Bock H. L. *et al.*                                1996  Prospective cohort                                                                                   28 ± 10.6                                                     Health care staff and their relatives    Germany                               176/704                                                 NA                                           0-1-6                                1 month                  20 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                 1989 IU/L                                                                                                                                                                                                                                                                                                           97.8%
  Averhoff F. *et al.*                               1998  Retrospective cohort                                                                                    41                                                         Health care workers                      USA                                  1335/416                                                 NA                                           0-1-6                                1 month                  recombinant vaccine, 20 μg Engerix-B and 10 μg Recombivax                                                IM                                                                                            \<40 years of age: a) 2138 IU/L in Engerix-B,b) 1047 IU/L in Recombivax-HB;≥40 years of age: a) 1000 IU/L in Engerix-B,b) 288 IU/L in Recombivax-HB                                                                                                                                                                                                                   a\) 90% in Engerix-B;b) 86% in Recombivax-HB
  Cardell K. *et al.*                                1999  Prospective cohort                                                                            Mean: 36 range: 19--63                                               Health care workers                      Sweden                               239/1167                                                 NA                                           0-1-6                                2 months                 2 μg recombinant vaccine, Engerix-B                                                                      ID                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               68.3%
  Ingardia C. J. *et al.*                            1999  Retrospective cohort                                                                         23.8 ± 5.6 range: 15--40                                              Pregnant women                           USA                                    0/80                                        27.7 ± 7.0 range: 18--56                                0-1-6                            11.1 ± 5.1 weeks             20 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               45.0%
  Young M. D. *et al.*                               2001  Randomized trials                                                                  a\) 39.2 range: 18--65 b) 38.8 range: 18--65                                    Healthy adults                           USA                                 a\) 62/90;                                                NA                                           0-1-6                               3--4 weeks                a\) 20 ug recombinant vaccine; Hepacare; b) 20 ug recombinant vaccine; Engerix-B                         IM                                                                                                                                           90% of vaccinees had titers ≥100 IU/L in both groups.                                                                                                                                                                                                                                                                              a\) 98% in Hepacare;
                                                                                                                                                                                                                                                                                                            b\) 60/91                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    b\) 88% in Engerix-B
  Wolters B. *et al.*                                2003  Retrospective cohort                                                                          Mean: 54 range: 17--84                                               Older adults                             Germany                                51/53                                                  NA                                           0-1-6                    16.8 months (range 1--36 months)     20 μg recombinant vaccine, Twinrix                                                                       IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               46.0%
  Martins R. M. *et al.*                             2004  Randomized trials                                                                              a\) 20--30 b) 31--40                                                Healthy adults                           Brazil                        a\) 364/114; b) 352/134                                         NA                                           0-1-6                              28--100 days               a\) 20 μg recombinant vaccine, Butang;b) 20 μg recombinant vaccine, Engerix-B                            IM           a\) Butang^®^, 351.1 in newborn infants, 3600.0 in children, 746.3 in adolescents, 453.5 in adults 20--30 years old, and 122.7 in adults 31--40 years old;b) Engerix-B, 1530.6 in newborn infants, 2753.1 in children, 1284.3 in adolescents, 1369.0 in adults 20--30 years old, and 686.2 in adults 31--40 years old   a\) Butang, 93.7% in newborn infants, 100% in children, 95.1% in adolescents, 91.8% in adults 20--30 years old, and 79.8% in adults 31--40 years old;b) Engerix-B, 97.5% in newborn infants, 97.7% in children, 96% in adolescents, 95.5% in adults 20--30 years old, and 92.4% in adults 31--40 years old
  Yen Y. H. *et al.*                                 2005  Retrospective cohort                                                                         Mean: 36.6 range: 25--70                                              Health care workers                      China                                 50/200                                                  NA                                           0-1-6                                8 months                 20 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                               5 of 8 responders were 10.5, 199.3, 396.9, 822.2 and 1000 IU/L, respectively.                                                                                                                                                                                                                                                                         86.4%
  Panhotra B. R. *et al.*                            2005  Retrospective cohort                                                                         34.6 ± 8.2 range: 21--60                                              Health care workers                      Saudi Arabia                          620/682                                                 NA                                           0-1-6                                3 months                 20 μg recombinant vaccine, Engerix                                                                       IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               92.2%
  Kulkarni P. S. *et al.*                            2006  Prospective cohort                                                                                  33 ± 8.645                                                     Healthy adults                           India                                 766/22                                              22.4 ± 2.8                                       0-1-6                                1 month                  20 μg recombinant vaccine, Batch                                                                         IM                                                                                                                                                                 443 IU/L                                                                                                                                                                                                                                                                                                            96.0%
  Estévez Z. C. *et al.*                             2006  Randomized trials                                                                                     20--64                                                       Healthy adults                           Cuba                                  167/293                                                 NA                                           0-1-2                                1 month                  20 μg recombinant vaccine, Heberbiovac HB                                                                IM                                                                                                                                                                931.18 IU/L                                                                                                                                                                                                                                                                                                          97.0%
  Locquet C. *et al.*                                2007  Retrospective cohort                                                                          35 ± 10.4 range: 17--65                                              Women healthcare workers                 France                                 0/880                                              23.4 ± 4.4                                   a\) 0-1-2-12;                         1--169 months               20 μg recombinant vaccine, Genhevac Pasteur/20 μg recombinant vaccine, Engerix GlaxoSmithKline           IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               92.0%
                                                                                                                                                                                                                                                                                                                                                                                                                b\) 0-1-6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Sabidó M. *et al.*                                 2007  Retrospective cohort                                                                                33 ± 10.51                                                     Health care workers                      Spain                                437/1621                                            23.50 ± 3.76                                      0-1-6                              1--6 months                17.4% plasma-derived vaccine, Hevac-B;                                                                   IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               92.2%
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                83.5% recombinant vaccine, Engerix-B                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Oliveira L. C. *et al.*                            2007  Randomized trials                                                            a\) 46.6 ± 10.9(alcoholics);b) 37.8 ± 9.7(non-alcoholics)                             Healthy adults                           Portugal                               60/0                                                   NA                                           0-1-6                                1 month                  20 μg recombinant vaccine, Euvax-B                                                                       IM                                                                                                                                    a\) 511 ± 448 IU/L (alcoholics);b) 696 ± 410 IU/L (non-alcoholics)                                                                                                                                                                                                                                                           a\) 50% (alcoholics);b) 52.5% (non-alcoholics)
  Wolters B. *et al.*                                2009  a\) Prospective cohort b) Retrospective cohort                               a\) Mean: 38.9 range: 18--79 b) Mean: 39.9 range: 16--75                              Healthy adults                           German                         a\) 109/65 b) 133/115                             a\) 25.5 ± 4.8 b) 24.4 ± 3.8                              0-1-6                              1--2 months                Twinrix                                                                                                  NA                                                                                                                                                                 1430 IU/L                                                                                                                                                                                                                                                                                                           88.7%
  Kevorkyan A. K. *et al.*                           2011  Retrospective cohort                                                                                40.3 ± 2.6                                                     Health care workers                      Bulgaria                               13/57                                                  NA                                           0-1-6                              1--2 months                20 μg recombinant vaccine, Hepavax Gen                                                                   NA                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               92.8%
  Sheffield J. S. *et al.*                           2011  Prospective cohort                                                                                  25.3 ± 5.2                                                     Pregnant women                           USA                                    0/168                                a\) 26(responder);b) 36(non-responder)                         0-1-4                              5--6 months                recombinant vaccine, Recombivax HB                                                                       IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               90.0%
  De Schryver A. *et al.*                            2011  Randomized trials                                                                          a\) 41.4 ± 10.4 b) 42.5 ± 9.8                                           Healthy volunteers                       Belgium                               310/61                                     a\) 26.1 ± 5.0 b) 26.6 ± 4.6                       a\) 0-1-6;b) 0-1-12                         1 month                  20 μg recombinant vaccine, Twinrix                                                                       IM                                                                                                                                              a\) 1900.6 IU/L (0-1-12); b) 749.0 IU/L (0-1-6)                                                                                                                                                                                                                                                                         a\) 95.6% (0-1-12);b) 97.1% (0-1-6)
  Tohme R. A. *et al.*                               2011  Retrospective cohort                                                                        82.2 ± 14.2 range: 45--102                                             Older adults                             USA                                    7/25                                               25.4 ± 4.6                                       0-1-4                              80--90 days                20 μg recombinant vaccine, Engerix-B                                                                     IM                                                                                                                                                                 4.8 IU/L                                                                                                                                                                                                                                                                                                            33.3%
  Ren J. J. *et al.*                                 2012  Retrospective cohort                                              a\) 32.45 ± 0.66 b) 33.69 ± 0.70 c) 31.71 ± 0.69 d) 32.20 ± 1.07 range: 16--49                   Healthy adults                           China             a\) 242/351; b) 182/283; c) 246/333; d) 101/134                             NA                                           0-1-6                                1 month                  10 μg recombinant vaccine producted by 4 different manufacturers                                         IM                                                                                                            a\) 177.28 IU/L (Kangtai);b) 473.23 IU/L (Dalian HTB);c) 246.13 IU/L (GeneTech BP);d) 332.20 IU/L (GlaxoSmithKline)                                                                                                                                                                                                         a\) 81.67% (Kangtai);b) 95.05% (Dalian HTB);c) 89.64% (GeneTech BP);d) 86.81% (GlaxoSmithKline)
  Williams R. E. *et al.*                            2012  Retrospective cohort                                                                        Median: 79.5 range 45--101                                             Older adults                             USA                                    39/47                                                  NA                                           0-1-6                              1--2 months                1 mldose recombinant vaccine, Twinrix                                                                    IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               34.0%
  Chathuranga L. S. *et al.*                         2013  Retrospective cohort                                                                                    NA                                                         Health care workers                      Sri Lanka                             190/152                                                 NA                                            NA                             2 months-14 years             NA                                                                                                       NA                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               92.1%
  Bender T. J. *et al.*                              2014  Retrospective cohort                                                                         Median: 60 range: 46--86                                              Adults with assisted living facilities   USA                                    17/10                                                  NA                                           0-1-7                              1--2 months                1 mldose recombinant vaccine, Twinrix                                                                    IM                                                                                                                                                                 91.7 IU/L                                                                                                                                                                                                                                                                                                           81.0%
  Thomas R. J. *et al.*                              2015  Retrospective cohort                                                                                  16--50                                                       Health care workers                      India                                 148/306                                                 NA                                           0-1-6                                1 month                  20 μg recombinant vaccine, GeneVac-B                                                                     IM                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               98.9%
  Nashibi R. *et al.*[\*](#t1-fn1){ref-type="fn"}    2015  Retrospective cohort                                                                         31.9 ± 18.1 range: 20--55                                             Health care workers                      Iran                                  43/196                        a\) 31.6 ± 7.5(responder);b) 33.4 ± 5.6(non-responder)                  NA                                1--6 months                NA                                                                                                       NA                                                                                                                                                                    NA                                                                                                                                                                                                                                                                                                               94.1%
  a\) Yao J. *et al.*                                2015  Randomized trials                                                                a\) 32.75 ± 7.93 b) 33.31 ± 7.71 c) 33.16 ± 8.00                                  Healthy adults                           China                   a\) 354/519; b) 338/523; c) 259/445                                   NA                              a\) 0-1-3; b) 0-1-6; c) 0-1-12                   12 months                 10 ug recombinant vaccine                                                                                IM                                                                                                                                 a\) 213.16 IU/L (0-1-3); b) 432.58 IU/L (0-1-6); c) 451.47 IU/L (0-1-12)                                                                                                                                                                                                                                                     a\) 100% (0-1-3);b) 99.9% (0-1-6);c) 97.9% (0-1-12)
  b\) Yao J. *et al.*                                2015  Randomized trials                                 a\) Median: 30.23 range: 20.01--39.76 b) Median: 29.42 range: 20.01--39.92 c) Median: 30.25 range: 20.10--39.98  Seronegative adults                      China                   a\) 100/149; b) 111/118; c) 84/124                                    NA                               a\) 0-1-3;b) 0-1-6;c) 0-1-12                     1 month                  10 ug recombinant vaccine                                                                                IM                                                                                                                                  a\) 61.19 IU/L (0-1-3);b) 214.04 IU/L (0-1-6); c) 345.78 IU/L (0-1-12)                                                                                                                                                                                                                                                      a\) 83.9% (0-1-3);b) 88.2% (0-1-6);c) 94.2% (0-1-12)

NA: not available; IM: intramuscular; ID: intradermal.

\*This article was regarded cross-sectional as cohort study.

###### The absolute and relative risk of non-response to HBV vaccine by subgroup and evidence quality grading[\*](#t2-fn1){ref-type="fn"}.

  Comparator                       Intervention         Illustrative comparative risks\*(per 1000, 95% CI)   Relative risk of non-response (95% CI)   Number of Participants (studies)   Quality of the evidence (GRADE)  
  ------------------------- -------------------------- ---------------------------------------------------- ---------------------------------------- ---------------------------------- --------------------------------- ---------------
  Age \< 40                          Age ≥ 40                                  105                                      195 (163 to 233)                    1.85 (1.55 to 2.21)                10233 (19 studies)            ⊕⊕⊕⊕ high
  Age \< 30                          Age ≥ 30                                   58                                       99 (81 to 121)                      1.72 (1.41 to 2.1)                 5372 (13 studies)          ⊕⊕⊕⊝ moderate
  Age \< 60                          Age ≥ 60                                  284                                      370 (287 to 478)                    1.30 (1.01 to 1.68)                  480 (5 studies)           ⊕⊕⊕⊝ moderate
  Female                               Male                                    124                                      176 (149 to 209)                     1.42 (1.2 to 1.68)                10118 (20 studies)            ⊕⊕⊕⊕ high
  BMI \< 25                          BMI ≥ 25                                  125                                      186 (134 to 255)                    1.48 (1.07 to 2.03)                 5807 (10 studies)          ⊕⊕⊕⊝ moderate
  Non-smoker                          Smoker                                   132                                      195 (152 to 248)                    1.47 (1.15 to 1.87)                 6935 (13 studies)            ⊕⊕⊕⊕ high
  Non-alcoholic                     Alcoholic                                   50                                       43 (29 to 63)                      0.86 (0.58 to 1.26)                 2381 (5 studies)           ⊕⊕⊕⊝ moderate
  Healthy                      Concomitant diseases                            100                                      140 (104 to 187)                    1.39 (1.04 to 1.86)                 4386 (12 studies)            ⊕⊕⊕⊕ high
  Vaccine at 0-1-6 months    Vaccine at 0-1-12 months                           32                                       45 (12 to 192)                     1.39 (0.41 to 4.67)                 2433 (4 studies)           ⊕⊝⊝⊝ very low

GRADE: Grading of Recommendations, Assessment, Development and Evaluation.

\*The results presented in the Table 2 were built around the assumption of a consistent relative effect. The implications of this effect for populations were considered at different baseline risks. Based on the assumed risks, corresponding risks after an intervention were calculated using the meta-analytic risk ratio.

[^1]: These authors contributed equally to this work.
